Dr. Siegall is one of the top researchers in the United States. He furthers the fight against cancer through a Bothell, Washington-based biotechnological company that develops antibody-based medications. These drugs have high targeting ability and transport cell-killing agents to the cancerous tumors and cells. Dr. Siegall was instrumental in the development and commercialization of ADCETRIS, which has aided in the treatment of 15,000 lymphoma patients around the world. He believes that ADCETRIS has a potential to lay the basis for treatment of CD30-expressing malignancies.
Seattle Genetics’ diverse pipeline
Seattle Genetics ventured into cancer research and development of ADCs back in 1998. Since then, Dr. Siegall has managed the company and guided it through the growth process. Currently, the firm has a diverse pipeline of high-quality antibody-based cancer drugs, including ADCETRIS that was licensed by the U.S. FDA in 2012. Clinical trials for the company’s 12 additional medications are generating a positive result. However, the SGN-CD33A and SGN-CD19A are two lead programs that have impressed Dr. Siegall.
SGN-CD33A is a unique antibody-based medication that targets CD33 that most acute leukemia cells express. Acute myeloid leukemia has become a serious medical condition, and the available drugs have failed to produce significant results. SGN-CD33A consists of three major portions: an anti-CD33 antibody made from cysteine that allows equal site-specific conjugation, a highly stable cleavable dipeptide linker, and a DNA-binder known as pyrrolobenzodiazepine.
This ADC targets CD19, a protein that B-cell malignancies broadly express. It consists of an anti-CD19 monoclonal antibody combined with an artificial cell-killing agent known as monomethyl auristatin F (MMAF). It is developed to maintain its stability in the bloodstream and generate its cytotoxic agent once internalized into tumor cells that express CD19.
Partnership and capital-raising activities
Dr. Siegall has negotiated numerous partnership and licensing deals for Seattle Genetics, including with GlaxoSmithKline, Roche, Pfizer, and AbbVie. These deals have yielded more than $300 million. Several internal and collaborator programs are capitalizing on Seattle’s technology to develop over 20 ADCs. The firm’s president has been in charge of capital-raising initiatives that have yielded more than $675 million via both private and public financings.
Learn more about Clay Siegall here: